Back row (L to R): Brandon Young, Brett Prigaro, Chandraiah Lagisetti, Stacey
Davis, Vince Boyd, Jake Slavish
Front row (L to R): Jeanine Price, Gustavo Palacios, Amanda Joyner, Thomas R.
Webb, Tino Goronga, Brandi Baughman, Parimala Hanumesh
Research in the Webb laboratory is focused on application of medicinal chemistry technology to lead discovery and chemical biology. Cancer lead discovery and lead optimization is a particular focus in the Webb laboratory encompassing a new target area in cancer; lead discovery for novel modulators of the spliceosome and alternate mRNA splicing, which was designed based on a natural product consensus pharmacophore. Another major project is the development of inhibitors of influenza endonuclease as novel influenza therapeutics in collaboration with Dr. Stephen White and Richard Webby. This latter project takes advantage of new assays and novel inhibitor/protein structures that our two labs have developed. Additionally we are actively pursuing the development of chemical biology tools for the elucidation of the widely used, but poorly understood, schistosomiasis drug, Praziquantel. Synthetic organic parallel, medicinal chemistry and new assay development are the major tools used in our laboratory. Molecular tool, lead design and synthesis are facilitated by integration with the High Throughput Chemistry facility. Our laboratory also has ongoing research in the development of cheminformatics and molecular modeling tools for the applied de novo design of ligands and new combinatorial templates based on pharmacophore information. Additionally the above efforts are complemented by an ongoing interest in the application of the most advanced work in organic synthesis, compound analysis and purification via application of enantioselective and diastereoselective synthesis along with chiral supercritical fluid chromatography (SFC), respectively.